PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18163430-2 2008 This study investigated the contribution of androgen receptor (AR) in the combined effect of TGF-beta and dihydrotestosterone (DHT), on regulation of apoptosis and AR- and TGF-beta mediated transcriptional activity in human prostate cancer cells. Dihydrotestosterone 106-125 transforming growth factor beta 1 Homo sapiens 172-180 18163430-2 2008 This study investigated the contribution of androgen receptor (AR) in the combined effect of TGF-beta and dihydrotestosterone (DHT), on regulation of apoptosis and AR- and TGF-beta mediated transcriptional activity in human prostate cancer cells. Dihydrotestosterone 127-130 transforming growth factor beta 1 Homo sapiens 172-180 18163430-4 2008 The apoptotic response to DHT/TGFbeta treatment was correlated with AR cellular distribution and the AR interaction with TGF-beta intracellular effector Smad4. Dihydrotestosterone 26-29 transforming growth factor beta 1 Homo sapiens 121-129 18163430-6 2008 TGF-beta1 induced transcriptional activity enhanced by DHT in both cell lines (LNCaP-TbetaRII and PC-3-AR) via AR-Smad4 interaction. Dihydrotestosterone 55-58 transforming growth factor beta 1 Homo sapiens 0-9 16257107-10 2005 TGFbeta1 reduced the E2F transcriptional activity of AR activation by DHT. Dihydrotestosterone 70-73 transforming growth factor beta 1 Homo sapiens 0-8 12242728-1 2002 BACKGROUND: We previously demonstrated that dihydrotestosterone (DHT) enhances transforming growth factor-beta (TGF-beta) -induced apoptosis in human prostate cancer cells (Endocrinology 2001;142:2419-2426). Dihydrotestosterone 44-63 transforming growth factor beta 1 Homo sapiens 79-110 12242728-1 2002 BACKGROUND: We previously demonstrated that dihydrotestosterone (DHT) enhances transforming growth factor-beta (TGF-beta) -induced apoptosis in human prostate cancer cells (Endocrinology 2001;142:2419-2426). Dihydrotestosterone 44-63 transforming growth factor beta 1 Homo sapiens 112-120 12242728-1 2002 BACKGROUND: We previously demonstrated that dihydrotestosterone (DHT) enhances transforming growth factor-beta (TGF-beta) -induced apoptosis in human prostate cancer cells (Endocrinology 2001;142:2419-2426). Dihydrotestosterone 65-68 transforming growth factor beta 1 Homo sapiens 79-110 12242728-1 2002 BACKGROUND: We previously demonstrated that dihydrotestosterone (DHT) enhances transforming growth factor-beta (TGF-beta) -induced apoptosis in human prostate cancer cells (Endocrinology 2001;142:2419-2426). Dihydrotestosterone 65-68 transforming growth factor beta 1 Homo sapiens 112-120 11918080-8 2002 The treatment of HBME monolayers with various combinations of cytokines and DHT prior to performing adhesion assays with PC-3 demonstrates that treatments containing TGF-beta reduced PC-3 cell adhesion to HBME monolayers by 32% or greater (P < 0.05). Dihydrotestosterone 76-79 transforming growth factor beta 1 Homo sapiens 166-174 11356690-0 2001 Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Dihydrotestosterone 0-19 transforming growth factor beta 1 Homo sapiens 29-60 11356690-2 2001 Surprisingly, when the LNCaP TGF-beta receptor II cells were treated with TGF-beta in the presence of physiological levels of DHT, both cell cycle arrest and apoptosis induction were significantly enhanced over TGF-beta alone. Dihydrotestosterone 126-129 transforming growth factor beta 1 Homo sapiens 29-37 11356690-2 2001 Surprisingly, when the LNCaP TGF-beta receptor II cells were treated with TGF-beta in the presence of physiological levels of DHT, both cell cycle arrest and apoptosis induction were significantly enhanced over TGF-beta alone. Dihydrotestosterone 126-129 transforming growth factor beta 1 Homo sapiens 74-82 11356690-2 2001 Surprisingly, when the LNCaP TGF-beta receptor II cells were treated with TGF-beta in the presence of physiological levels of DHT, both cell cycle arrest and apoptosis induction were significantly enhanced over TGF-beta alone. Dihydrotestosterone 126-129 transforming growth factor beta 1 Homo sapiens 74-82 10881022-4 2000 Results of our previous study demonstrated that the inhibitory effect of DHT at a high concentration was mediated through the action of TGF-beta1. Dihydrotestosterone 73-76 transforming growth factor beta 1 Homo sapiens 136-145 10706107-3 2000 Treatment of ovarian cancer HEY cells with 500 nM 5alpha-dihydrotestosterone (DHT), but not estradiol-17beta or progesterone, for 60 h down-regulated the expression of mRNA for TGF-beta receptors I and II (TbetaR-I and TbetaR-II), betaglycan, and endoglin but had no effect on TGF-beta1 mRNA levels. Dihydrotestosterone 50-76 transforming growth factor beta 1 Homo sapiens 177-185 10706107-3 2000 Treatment of ovarian cancer HEY cells with 500 nM 5alpha-dihydrotestosterone (DHT), but not estradiol-17beta or progesterone, for 60 h down-regulated the expression of mRNA for TGF-beta receptors I and II (TbetaR-I and TbetaR-II), betaglycan, and endoglin but had no effect on TGF-beta1 mRNA levels. Dihydrotestosterone 50-76 transforming growth factor beta 1 Homo sapiens 277-286 10706107-3 2000 Treatment of ovarian cancer HEY cells with 500 nM 5alpha-dihydrotestosterone (DHT), but not estradiol-17beta or progesterone, for 60 h down-regulated the expression of mRNA for TGF-beta receptors I and II (TbetaR-I and TbetaR-II), betaglycan, and endoglin but had no effect on TGF-beta1 mRNA levels. Dihydrotestosterone 78-81 transforming growth factor beta 1 Homo sapiens 177-185 10706107-3 2000 Treatment of ovarian cancer HEY cells with 500 nM 5alpha-dihydrotestosterone (DHT), but not estradiol-17beta or progesterone, for 60 h down-regulated the expression of mRNA for TGF-beta receptors I and II (TbetaR-I and TbetaR-II), betaglycan, and endoglin but had no effect on TGF-beta1 mRNA levels. Dihydrotestosterone 78-81 transforming growth factor beta 1 Homo sapiens 277-286 10706107-10 2000 DHT was able to reverse TGF-beta1 growth-inhibitory action in SKOV-3 cells and in a primary culture of ovarian cancer cells derived from ascites. Dihydrotestosterone 0-3 transforming growth factor beta 1 Homo sapiens 24-33 10690900-4 2000 To address potential TGFbeta1 induction by DHT, quantitative PCR and enzyme-linked immunoadsorbent assay were performed in NCI-H295 cells treated with DHT (from 10(-12)-10(-9) mol/L). Dihydrotestosterone 43-46 transforming growth factor beta 1 Homo sapiens 21-29 10690900-5 2000 DHT led to a significant dose-dependent increase in TGFbeta1 messenger ribonucleic acid expression and in biologically active TGFbeta1 protein levels in the conditioned media of NCI-H295 cells, demonstrating that androgen can induce TGFbeta1 expression and production. Dihydrotestosterone 0-3 transforming growth factor beta 1 Homo sapiens 52-60 10690900-5 2000 DHT led to a significant dose-dependent increase in TGFbeta1 messenger ribonucleic acid expression and in biologically active TGFbeta1 protein levels in the conditioned media of NCI-H295 cells, demonstrating that androgen can induce TGFbeta1 expression and production. Dihydrotestosterone 0-3 transforming growth factor beta 1 Homo sapiens 126-134 10690900-5 2000 DHT led to a significant dose-dependent increase in TGFbeta1 messenger ribonucleic acid expression and in biologically active TGFbeta1 protein levels in the conditioned media of NCI-H295 cells, demonstrating that androgen can induce TGFbeta1 expression and production. Dihydrotestosterone 0-3 transforming growth factor beta 1 Homo sapiens 126-134 10690900-7 2000 The addition of TGFbeta1-neutralizing antibody to cell cultures treated with different DHT concentrations (10(-9) and 10(-10) mol/L) blocked the inhibitory effect of TGF/beta1 on adrenocortical cell proliferation. Dihydrotestosterone 87-90 transforming growth factor beta 1 Homo sapiens 16-24 10690900-7 2000 The addition of TGFbeta1-neutralizing antibody to cell cultures treated with different DHT concentrations (10(-9) and 10(-10) mol/L) blocked the inhibitory effect of TGF/beta1 on adrenocortical cell proliferation. Dihydrotestosterone 87-90 transforming growth factor beta 1 Homo sapiens 166-175 10690900-9 2000 Therefore, it might be reasonable to suppose that DHT could also influence human adrenocortical cell growth by involving TGFbeta1. Dihydrotestosterone 50-53 transforming growth factor beta 1 Homo sapiens 121-129 10534066-8 1999 There were significant increases in the formation of DHT from 14C-T in response to M, TGF-beta, and PDGF, alone and in combination (13 to 48%), compared with controls (n = 4; P<0.01). Dihydrotestosterone 53-56 transforming growth factor beta 1 Homo sapiens 86-94 10420148-8 1999 The inhibition of (3)H-thymidine incorporation by TGFbeta1 was more pronounced in the absence of dihydrotestosterone (DHT) than in its presence, and melatonin had no further effect. Dihydrotestosterone 97-116 transforming growth factor beta 1 Homo sapiens 50-58 10420148-8 1999 The inhibition of (3)H-thymidine incorporation by TGFbeta1 was more pronounced in the absence of dihydrotestosterone (DHT) than in its presence, and melatonin had no further effect. Dihydrotestosterone 118-121 transforming growth factor beta 1 Homo sapiens 50-58 9736458-6 1998 Steady-state levels of transforming growth factor-beta1 (TGF-beta1) and TGF-beta-induced early gene (TIEG) mRNA decreased after treatment of hFOB/AR-6 cells with 5alpha-DHT, suggesting a role for the TGF-beta1-TIEG pathway in mediating 5alpha-DHT-induced growth inhibition of hFOB/AR-6 cells. Dihydrotestosterone 162-172 transforming growth factor beta 1 Homo sapiens 23-55 9736458-6 1998 Steady-state levels of transforming growth factor-beta1 (TGF-beta1) and TGF-beta-induced early gene (TIEG) mRNA decreased after treatment of hFOB/AR-6 cells with 5alpha-DHT, suggesting a role for the TGF-beta1-TIEG pathway in mediating 5alpha-DHT-induced growth inhibition of hFOB/AR-6 cells. Dihydrotestosterone 162-172 transforming growth factor beta 1 Homo sapiens 57-66 9736458-6 1998 Steady-state levels of transforming growth factor-beta1 (TGF-beta1) and TGF-beta-induced early gene (TIEG) mRNA decreased after treatment of hFOB/AR-6 cells with 5alpha-DHT, suggesting a role for the TGF-beta1-TIEG pathway in mediating 5alpha-DHT-induced growth inhibition of hFOB/AR-6 cells. Dihydrotestosterone 162-172 transforming growth factor beta 1 Homo sapiens 200-209 9736458-6 1998 Steady-state levels of transforming growth factor-beta1 (TGF-beta1) and TGF-beta-induced early gene (TIEG) mRNA decreased after treatment of hFOB/AR-6 cells with 5alpha-DHT, suggesting a role for the TGF-beta1-TIEG pathway in mediating 5alpha-DHT-induced growth inhibition of hFOB/AR-6 cells. Dihydrotestosterone 236-246 transforming growth factor beta 1 Homo sapiens 23-55 9736458-7 1998 In support of this, co-treatment of hFOB/AR-6 cells with TGF-beta1 (40 pg/ml) reversed the 5alpha-DHT-induced growth inhibition, whereas TGF-beta1 alone at this dose had no effect on hFOB/AR-6 cell proliferation. Dihydrotestosterone 91-101 transforming growth factor beta 1 Homo sapiens 57-66 9722268-4 1998 Similarly, PDGF/TGF-beta resulted in a 2-fold increase in DHT synthesis over controls (n=5; p<0.01) which compared with individual PDGF incubations, and the TGF-beta/IGF combination resulted in a 30% increase in DHT synthesis over controls (n=3; p<0.01); this was less than the 2.8/2.5-fold increases produced individually. Dihydrotestosterone 58-61 transforming growth factor beta 1 Homo sapiens 16-24 9722268-4 1998 Similarly, PDGF/TGF-beta resulted in a 2-fold increase in DHT synthesis over controls (n=5; p<0.01) which compared with individual PDGF incubations, and the TGF-beta/IGF combination resulted in a 30% increase in DHT synthesis over controls (n=3; p<0.01); this was less than the 2.8/2.5-fold increases produced individually. Dihydrotestosterone 215-218 transforming growth factor beta 1 Homo sapiens 16-24 9722268-5 1998 Similarly, when 14C-4-androstenedione was used as the substrate, there were 2-fold increases in DHT synthesis in response to combinations of PDGF/IGF and PDGF/TGF-beta (n=5; p<0.01). Dihydrotestosterone 96-99 transforming growth factor beta 1 Homo sapiens 159-167 9633523-2 1998 Yet, these cells respond to exogenous TGF-beta 1 under appropriate concentrations of dihydrotestosterone (DHT). Dihydrotestosterone 85-104 transforming growth factor beta 1 Homo sapiens 38-48 9633523-2 1998 Yet, these cells respond to exogenous TGF-beta 1 under appropriate concentrations of dihydrotestosterone (DHT). Dihydrotestosterone 106-109 transforming growth factor beta 1 Homo sapiens 38-48 9633523-5 1998 Results of Western blot analysis showed that LNCaP cells express an increased level of type II receptor at 0.1 nM DHT, the TGF-beta 1-sensitive dose. Dihydrotestosterone 114-117 transforming growth factor beta 1 Homo sapiens 123-133 9618778-5 1998 This study examines a possible role for TGF beta 1 in mediating the DHT-induced reduction of human adrenocortical cell growth. Dihydrotestosterone 68-71 transforming growth factor beta 1 Homo sapiens 40-50 9618778-6 1998 TGF beta 1 and its receptor (TGF beta RII) are expressed in DHT-treated and nontreated NCI-H295 cells; on Northern blot analysis 24-h treatment with DHT (10(-11) M) produced a small increase in TGF beta RII RNA, and quantitative RT-PCR showed a 1.5-fold increase in TGF beta 1 RNA levels. Dihydrotestosterone 60-63 transforming growth factor beta 1 Homo sapiens 0-10 9618778-6 1998 TGF beta 1 and its receptor (TGF beta RII) are expressed in DHT-treated and nontreated NCI-H295 cells; on Northern blot analysis 24-h treatment with DHT (10(-11) M) produced a small increase in TGF beta RII RNA, and quantitative RT-PCR showed a 1.5-fold increase in TGF beta 1 RNA levels. Dihydrotestosterone 60-63 transforming growth factor beta 1 Homo sapiens 0-8 9618778-6 1998 TGF beta 1 and its receptor (TGF beta RII) are expressed in DHT-treated and nontreated NCI-H295 cells; on Northern blot analysis 24-h treatment with DHT (10(-11) M) produced a small increase in TGF beta RII RNA, and quantitative RT-PCR showed a 1.5-fold increase in TGF beta 1 RNA levels. Dihydrotestosterone 60-63 transforming growth factor beta 1 Homo sapiens 29-37 9618778-6 1998 TGF beta 1 and its receptor (TGF beta RII) are expressed in DHT-treated and nontreated NCI-H295 cells; on Northern blot analysis 24-h treatment with DHT (10(-11) M) produced a small increase in TGF beta RII RNA, and quantitative RT-PCR showed a 1.5-fold increase in TGF beta 1 RNA levels. Dihydrotestosterone 60-63 transforming growth factor beta 1 Homo sapiens 266-276 9618778-6 1998 TGF beta 1 and its receptor (TGF beta RII) are expressed in DHT-treated and nontreated NCI-H295 cells; on Northern blot analysis 24-h treatment with DHT (10(-11) M) produced a small increase in TGF beta RII RNA, and quantitative RT-PCR showed a 1.5-fold increase in TGF beta 1 RNA levels. Dihydrotestosterone 149-152 transforming growth factor beta 1 Homo sapiens 0-10 9618778-6 1998 TGF beta 1 and its receptor (TGF beta RII) are expressed in DHT-treated and nontreated NCI-H295 cells; on Northern blot analysis 24-h treatment with DHT (10(-11) M) produced a small increase in TGF beta RII RNA, and quantitative RT-PCR showed a 1.5-fold increase in TGF beta 1 RNA levels. Dihydrotestosterone 149-152 transforming growth factor beta 1 Homo sapiens 0-8 9618778-6 1998 TGF beta 1 and its receptor (TGF beta RII) are expressed in DHT-treated and nontreated NCI-H295 cells; on Northern blot analysis 24-h treatment with DHT (10(-11) M) produced a small increase in TGF beta RII RNA, and quantitative RT-PCR showed a 1.5-fold increase in TGF beta 1 RNA levels. Dihydrotestosterone 149-152 transforming growth factor beta 1 Homo sapiens 29-37 9618778-6 1998 TGF beta 1 and its receptor (TGF beta RII) are expressed in DHT-treated and nontreated NCI-H295 cells; on Northern blot analysis 24-h treatment with DHT (10(-11) M) produced a small increase in TGF beta RII RNA, and quantitative RT-PCR showed a 1.5-fold increase in TGF beta 1 RNA levels. Dihydrotestosterone 149-152 transforming growth factor beta 1 Homo sapiens 266-276 9618778-7 1998 These findings suggest that TGF beta 1 and its receptor may be involved in DHT-induced inhibition of human adrenocortical cell growth. Dihydrotestosterone 75-78 transforming growth factor beta 1 Homo sapiens 28-38 9076590-8 1997 This indicates that DHT and DHEA (1) exert their mitogenic effects by androgen receptor-mediated mechanisms, (2) stimulate ALP production by increased TGF-beta expression, (3) that the action of DHT is not affected by the presence of 4-MA, and that (4) DHEA does not need to be metabolized by 3 beta HSD or 5-AR first to exert its effects on HOCs in vitro. Dihydrotestosterone 20-23 transforming growth factor beta 1 Homo sapiens 151-159 8665481-14 1996 We determined that DHT can induce the basal-like cells to secrete transforming growth factor-beta (TGF-beta 1), and that TGF-beta 1 can inhibit the proliferation of LNCaP cells in a dose dependent manner. Dihydrotestosterone 19-22 transforming growth factor beta 1 Homo sapiens 99-109 8665481-15 1996 We conclude that basal-like epithelial cells, in the presence of DHT, secrete an extracellular matrix o matrix associated factor(s), e.g. TGF-beta 1, that suppresses proliferation and function of prostate cancer cells. Dihydrotestosterone 65-68 transforming growth factor beta 1 Homo sapiens 138-148 8858535-0 1996 The synthesis of 5-alpha-dihydrotestosterone from androgens by human gingival tissues and fibroblasts in culture in response to TGF-beta and PDGF. Dihydrotestosterone 17-44 transforming growth factor beta 1 Homo sapiens 128-136 8858535-5 1996 With HGT, TGF-beta and PDGF caused 2.5/2-fold increases in DHT synthesis (p < 0.1; Wilcoxon signed rank test) and 3.4/2-fold increases in 4-androstenedione formation (p < 0.1) from 14C-testosterone. Dihydrotestosterone 59-62 transforming growth factor beta 1 Homo sapiens 10-18 8858535-7 1996 With cell-lines, average values of duplicate incubations showed 2.8/2-fold increases in DHT synthesis from 14C-testosterone in response to TGF-beta/PDGF (p < 0.1; p < 0.2) and 2.4/2-fold increases in 4-androstenedione synthesis (p < 0.1; p < 0.2). Dihydrotestosterone 88-91 transforming growth factor beta 1 Homo sapiens 139-147 8858535-8 1996 With 14C-4-androstenedione as substrate, TGF-beta/PDGF caused 1.6/1.9-fold increases in DHT synthesis compared with controls (p < 0.05; p < 0.1) and 1.7/1.5-fold increases in testosterone formation from this substrate (p < 0.05; p < 0.1). Dihydrotestosterone 88-91 transforming growth factor beta 1 Homo sapiens 41-49 8858535-9 1996 Due to the strong implications of TGF-beta/PDGF and anabolic androgens on matrix repair, significant increases in DHT synthesis from 2 androgenic substrates in response to TGF-beta and PDGF are of particular relevance to inflammatory repair processes. Dihydrotestosterone 114-117 transforming growth factor beta 1 Homo sapiens 34-42 8858535-9 1996 Due to the strong implications of TGF-beta/PDGF and anabolic androgens on matrix repair, significant increases in DHT synthesis from 2 androgenic substrates in response to TGF-beta and PDGF are of particular relevance to inflammatory repair processes. Dihydrotestosterone 114-117 transforming growth factor beta 1 Homo sapiens 172-180 8603613-6 1996 Competitive quantitative RT-PCR demonstrated that the level of TGF-beta1 messenger RNA increased approximately 7-fold when cells were treated with 10(-7) M DHT. Dihydrotestosterone 156-159 transforming growth factor beta 1 Homo sapiens 63-72 8603613-7 1996 Results of Western blot analysis showed a dramatic increase in the level of latent TGF-beta1 protein in cell lysates with increasing concentrations of DHT. Dihydrotestosterone 151-154 transforming growth factor beta 1 Homo sapiens 83-92 8603613-8 1996 In addition, results of enzyme-linked immunoadsorbent assay for TGF-beta1 indicated that treatment of LNCaP cells with DHT led to a dose-dependent increase in both total and biologically active TGF-beta1 in the conditioned media. Dihydrotestosterone 119-122 transforming growth factor beta 1 Homo sapiens 64-73 8603613-8 1996 In addition, results of enzyme-linked immunoadsorbent assay for TGF-beta1 indicated that treatment of LNCaP cells with DHT led to a dose-dependent increase in both total and biologically active TGF-beta1 in the conditioned media. Dihydrotestosterone 119-122 transforming growth factor beta 1 Homo sapiens 194-203 8603613-10 1996 First, TGF-beta1 neutralizing antibody was added to the culture medium with varying concentrations of DHT. Dihydrotestosterone 102-105 transforming growth factor beta 1 Homo sapiens 7-16 8603613-13 1996 These observations, taken together, indicate that TGF-beta1 mediates at least in part the growth arrest observed at the high concentration of DHT in LNCaP cells. Dihydrotestosterone 142-145 transforming growth factor beta 1 Homo sapiens 50-59 8549651-2 1996 In the present study, we have used LNCaP cells as a model of androgen-responsive prostate cancer to investigate the effects of dihydrotestosterone (DHT) on the sensitivity to TGF-beta 1. Dihydrotestosterone 127-146 transforming growth factor beta 1 Homo sapiens 175-185 8549651-2 1996 In the present study, we have used LNCaP cells as a model of androgen-responsive prostate cancer to investigate the effects of dihydrotestosterone (DHT) on the sensitivity to TGF-beta 1. Dihydrotestosterone 148-151 transforming growth factor beta 1 Homo sapiens 175-185 8549651-9 1996 Of the various DHT concentrations investigated in this study, these effects of TGF-beta 1 on LNCaP cells were consistently demonstrated only at 10(-10) M. At other concentrations, the effects of TGF-beta 1 were either minimal or undetectable. Dihydrotestosterone 15-18 transforming growth factor beta 1 Homo sapiens 79-89 8549651-11 1996 These results indicate that LNCaP cells can be induced by DHT to respond to TGF-beta 1 and that DHT modulates the sensitivity to TGF-beta 1 and the level of TGF-beta receptor type II in these cells. Dihydrotestosterone 58-61 transforming growth factor beta 1 Homo sapiens 76-86 8549651-11 1996 These results indicate that LNCaP cells can be induced by DHT to respond to TGF-beta 1 and that DHT modulates the sensitivity to TGF-beta 1 and the level of TGF-beta receptor type II in these cells. Dihydrotestosterone 58-61 transforming growth factor beta 1 Homo sapiens 76-84 8549651-11 1996 These results indicate that LNCaP cells can be induced by DHT to respond to TGF-beta 1 and that DHT modulates the sensitivity to TGF-beta 1 and the level of TGF-beta receptor type II in these cells. Dihydrotestosterone 96-99 transforming growth factor beta 1 Homo sapiens 129-139 7796940-7 1995 In contrast, exposure of cells to an androgen (10(-7) M) and TGF-beta (2 x 10(-10) M) led to synergistic effects on 5 alpha R activity (control 1.5 +/- 0.1%, DHT 2.6 +/- 0.2% TGF-beta 1 4.8 +/- 0.5, TGF-beta 1 + DHT 9.2 +/- 1.2%). Dihydrotestosterone 158-161 transforming growth factor beta 1 Homo sapiens 61-69 7796940-7 1995 In contrast, exposure of cells to an androgen (10(-7) M) and TGF-beta (2 x 10(-10) M) led to synergistic effects on 5 alpha R activity (control 1.5 +/- 0.1%, DHT 2.6 +/- 0.2% TGF-beta 1 4.8 +/- 0.5, TGF-beta 1 + DHT 9.2 +/- 1.2%). Dihydrotestosterone 212-215 transforming growth factor beta 1 Homo sapiens 61-69 2229290-8 1990 This indicated that in addition to increased release of TGF beta, another mechanism might be involved in the action of DHT on human and murine bone cells. Dihydrotestosterone 119-122 transforming growth factor beta 1 Homo sapiens 56-64 35050457-11 2022 Compared with the Control group, the expression of collagen I, fibronectin, TGF-beta1 and Smad3 was decreased, and the expression of elastin and Smad7 was increased in WPMY-1 cells after treatment with 10 nM DHT (p < 0.01). Dihydrotestosterone 208-211 transforming growth factor beta 1 Homo sapiens 76-85 35050457-12 2022 Following treatment with 10 nM DHT, the expression of collagen I, fibronectin, TGF-beta1, and Smad3 was increased, and the expression of elastin and Smad7 was decreased in WPMY-1 cells with increasing E2 concentration treatment compared to the 10 nM DHT group (p < 0.05, p < 0.01). Dihydrotestosterone 31-34 transforming growth factor beta 1 Homo sapiens 79-88 35050457-13 2022 Following treatment with 5 pM E2, the expression of collagen I, fibronectin, TGF-beta1, and Smad3 was decreased, and elastin and Smad7 expression was increased with increasing DHT concentration compared to the 5 pM E2 group (p < 0.05, p < 0.01). Dihydrotestosterone 176-179 transforming growth factor beta 1 Homo sapiens 77-86 26091707-0 2016 Role of dihydrotestosterone (DHT) on TGF-beta1 signaling pathway in epithelial ovarian cancer cells. Dihydrotestosterone 8-27 transforming growth factor beta 1 Homo sapiens 37-46 26091707-0 2016 Role of dihydrotestosterone (DHT) on TGF-beta1 signaling pathway in epithelial ovarian cancer cells. Dihydrotestosterone 29-32 transforming growth factor beta 1 Homo sapiens 37-46 26091707-2 2016 The purpose of the present study was to evaluate whether DHT causes changes in the TGF-beta1 pathway that might modify the anti-proliferative effect of the latter. Dihydrotestosterone 57-60 transforming growth factor beta 1 Homo sapiens 83-92 26091707-7 2016 Additionally, after treatment of cell lines with DHT, protein levels of TGF-beta1 receptors (TGFBR1-TGFBR2) showed a decrease (p < 0.05) that might cause a potential disorder in TGF-beta1 response, represented by the significant decrease in p21 protein levels in the presence of DHT (p < 0.001). Dihydrotestosterone 49-52 transforming growth factor beta 1 Homo sapiens 72-81 26091707-7 2016 Additionally, after treatment of cell lines with DHT, protein levels of TGF-beta1 receptors (TGFBR1-TGFBR2) showed a decrease (p < 0.05) that might cause a potential disorder in TGF-beta1 response, represented by the significant decrease in p21 protein levels in the presence of DHT (p < 0.001). Dihydrotestosterone 49-52 transforming growth factor beta 1 Homo sapiens 181-190 26091707-7 2016 Additionally, after treatment of cell lines with DHT, protein levels of TGF-beta1 receptors (TGFBR1-TGFBR2) showed a decrease (p < 0.05) that might cause a potential disorder in TGF-beta1 response, represented by the significant decrease in p21 protein levels in the presence of DHT (p < 0.001). Dihydrotestosterone 282-285 transforming growth factor beta 1 Homo sapiens 72-81 26187065-7 2015 Still, DHT suppresses TGF-beta induced IGF-I promoter activity, but not its effects on DNA or collagen synthesis. Dihydrotestosterone 7-10 transforming growth factor beta 1 Homo sapiens 22-30 26187065-10 2015 Thus DHT suppresses the PGE2 and TGF-beta induced IGF-I gene promoter and differentiates other aspects of TGF-beta activity in osteoblasts. Dihydrotestosterone 5-8 transforming growth factor beta 1 Homo sapiens 33-41 26187065-10 2015 Thus DHT suppresses the PGE2 and TGF-beta induced IGF-I gene promoter and differentiates other aspects of TGF-beta activity in osteoblasts. Dihydrotestosterone 5-8 transforming growth factor beta 1 Homo sapiens 106-114 25315188-6 2015 Moreover, application of active AR ligand 5alpha-dihydrotestosterone (DHT) significantly decreased the effect of TGFbeta1 on GBM growth and apoptosis, suggesting that AR signaling pathway may contradict the effect of TGFbeta receptor signaling in GBM. Dihydrotestosterone 42-68 transforming growth factor beta 1 Homo sapiens 113-121 25315188-6 2015 Moreover, application of active AR ligand 5alpha-dihydrotestosterone (DHT) significantly decreased the effect of TGFbeta1 on GBM growth and apoptosis, suggesting that AR signaling pathway may contradict the effect of TGFbeta receptor signaling in GBM. Dihydrotestosterone 42-68 transforming growth factor beta 1 Homo sapiens 113-120 25315188-6 2015 Moreover, application of active AR ligand 5alpha-dihydrotestosterone (DHT) significantly decreased the effect of TGFbeta1 on GBM growth and apoptosis, suggesting that AR signaling pathway may contradict the effect of TGFbeta receptor signaling in GBM. Dihydrotestosterone 70-73 transforming growth factor beta 1 Homo sapiens 113-121 25315188-6 2015 Moreover, application of active AR ligand 5alpha-dihydrotestosterone (DHT) significantly decreased the effect of TGFbeta1 on GBM growth and apoptosis, suggesting that AR signaling pathway may contradict the effect of TGFbeta receptor signaling in GBM. Dihydrotestosterone 70-73 transforming growth factor beta 1 Homo sapiens 113-120 21765438-6 2011 Under treatment with DHT plus E2, PZsc secreted more transforming growth factor-beta1 (TGF-beta1) than TZsc, but this pattern was reversed when the cells were treated with E2 only. Dihydrotestosterone 21-24 transforming growth factor beta 1 Homo sapiens 53-85 21765438-6 2011 Under treatment with DHT plus E2, PZsc secreted more transforming growth factor-beta1 (TGF-beta1) than TZsc, but this pattern was reversed when the cells were treated with E2 only. Dihydrotestosterone 21-24 transforming growth factor beta 1 Homo sapiens 87-96 20739403-0 2010 DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells. Dihydrotestosterone 0-3 transforming growth factor beta 1 Homo sapiens 40-48 20739403-2 2010 We have recently reported that 5alpha-dihydrotestosterone (DHT) suppresses the ability of TGF-beta to inhibit proliferation and induce apoptosis of prostatic epithelial cells and provided evidence that such suppression was fueled by transcriptional down-regulation of TGF-beta receptor II (TaubetaRII). Dihydrotestosterone 31-57 transforming growth factor beta 1 Homo sapiens 90-98 20739403-2 2010 We have recently reported that 5alpha-dihydrotestosterone (DHT) suppresses the ability of TGF-beta to inhibit proliferation and induce apoptosis of prostatic epithelial cells and provided evidence that such suppression was fueled by transcriptional down-regulation of TGF-beta receptor II (TaubetaRII). Dihydrotestosterone 31-57 transforming growth factor beta 1 Homo sapiens 268-276 20739403-2 2010 We have recently reported that 5alpha-dihydrotestosterone (DHT) suppresses the ability of TGF-beta to inhibit proliferation and induce apoptosis of prostatic epithelial cells and provided evidence that such suppression was fueled by transcriptional down-regulation of TGF-beta receptor II (TaubetaRII). Dihydrotestosterone 59-62 transforming growth factor beta 1 Homo sapiens 90-98 20739403-2 2010 We have recently reported that 5alpha-dihydrotestosterone (DHT) suppresses the ability of TGF-beta to inhibit proliferation and induce apoptosis of prostatic epithelial cells and provided evidence that such suppression was fueled by transcriptional down-regulation of TGF-beta receptor II (TaubetaRII). Dihydrotestosterone 59-62 transforming growth factor beta 1 Homo sapiens 268-276 20739403-3 2010 We now show that androgen receptor (AR) activated by DHT suppresses the TGF-beta-induced phosphorylation of Sma- and Mad-related protein (Smad)3 in LNCaP cells overexpressing TbetaRII under the control of a cytomegalovirus promoter, which is not regulated by DHT, suggesting that transcriptional repression of TbetaRII alone does not fully account for the impact of DHT on TGF-beta responses. Dihydrotestosterone 53-56 transforming growth factor beta 1 Homo sapiens 72-80 20739403-3 2010 We now show that androgen receptor (AR) activated by DHT suppresses the TGF-beta-induced phosphorylation of Sma- and Mad-related protein (Smad)3 in LNCaP cells overexpressing TbetaRII under the control of a cytomegalovirus promoter, which is not regulated by DHT, suggesting that transcriptional repression of TbetaRII alone does not fully account for the impact of DHT on TGF-beta responses. Dihydrotestosterone 53-56 transforming growth factor beta 1 Homo sapiens 373-381 20739403-3 2010 We now show that androgen receptor (AR) activated by DHT suppresses the TGF-beta-induced phosphorylation of Sma- and Mad-related protein (Smad)3 in LNCaP cells overexpressing TbetaRII under the control of a cytomegalovirus promoter, which is not regulated by DHT, suggesting that transcriptional repression of TbetaRII alone does not fully account for the impact of DHT on TGF-beta responses. Dihydrotestosterone 259-262 transforming growth factor beta 1 Homo sapiens 72-80 20739403-3 2010 We now show that androgen receptor (AR) activated by DHT suppresses the TGF-beta-induced phosphorylation of Sma- and Mad-related protein (Smad)3 in LNCaP cells overexpressing TbetaRII under the control of a cytomegalovirus promoter, which is not regulated by DHT, suggesting that transcriptional repression of TbetaRII alone does not fully account for the impact of DHT on TGF-beta responses. Dihydrotestosterone 259-262 transforming growth factor beta 1 Homo sapiens 72-80 20739403-6 2010 Moreover, we show that overexpression of Smad3 reverses the ability of DHT to protect against TGF-beta-induced apoptosis in NRP-154+AR, supporting our model that loss of Smad3 by DHT is involved in the protection against TGF-beta-induced apoptosis. Dihydrotestosterone 71-74 transforming growth factor beta 1 Homo sapiens 94-102 20739403-6 2010 Moreover, we show that overexpression of Smad3 reverses the ability of DHT to protect against TGF-beta-induced apoptosis in NRP-154+AR, supporting our model that loss of Smad3 by DHT is involved in the protection against TGF-beta-induced apoptosis. Dihydrotestosterone 71-74 transforming growth factor beta 1 Homo sapiens 221-229 20739403-6 2010 Moreover, we show that overexpression of Smad3 reverses the ability of DHT to protect against TGF-beta-induced apoptosis in NRP-154+AR, supporting our model that loss of Smad3 by DHT is involved in the protection against TGF-beta-induced apoptosis. Dihydrotestosterone 179-182 transforming growth factor beta 1 Homo sapiens 94-102 20503393-11 2010 Downregulation of TGFB1 expression was induced by PA. FGF2 increased cells sensitivity to PA. Incubation with other mitogenic factors like VEGF, DHT, and E2 decreased sensitivity to PA. Dihydrotestosterone 145-148 transforming growth factor beta 1 Homo sapiens 18-23 19277688-4 2009 Treatment of HaCaT with dihydrotestosterone, which is known to be a primary factor of AGA, resulted in a concentration-dependent increase in TGF-beta1 promoter activity. Dihydrotestosterone 24-43 transforming growth factor beta 1 Homo sapiens 141-150